rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ASND
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Dow Plunges 900 Points On Salesforce Carnage: Paycom, Ascendis, TGTX In Focus - Video - IBD
      Nov 17Investor's Business DailyASNDCRMPAYC
      Jefferies reiterates Buy on Ascendis Pharma stock, $300 target
      Nov 17Investing.comASNDJEF
      Ascendis, Among Top 1%, Leads 9 Onto Best Stock Lists

      Ascendis rose 3% Friday and is nearing its record high, set in July. It's among 10 new to best stock lists.

      Nov 14Investor's Business DailyASND
      TD Cowen raises Ascendis Pharma stock price target on revenue beat
      Nov 13Investing.comASND
      Raymond James reiterates Ascendis Pharma stock rating on Yorvipath growth
      Nov 13Investing.comASND
      Ascendis Pharma (ASND) Could Be 12% Below Fair Value Following Q3 Earnings
      Nov 13Yahoo FinanceASND
      Ascendis Pharma (ASND) Stock Looks About Right After An 18% Rise
      Nov 13Yahoo FinanceASND
      Wells Fargo raises Ascendis Pharma stock price target on growth outlook
      Nov 13Investing.comASND
      Ascendis Pharma earnings analysis: questions answered and next catalysts
      Nov 12Investing.comASND
      Why is Ascendis Pharma stock climbing today?
      Nov 12Investing.comASND
      Ascendis Pharma A/S Q3 Earnings Call Highlights
      Nov 12Yahoo FinanceASND
      Earnings call transcript: Ascendis Pharma tops Q3 2026 estimates on strong growth
      Nov 12Investing.comASND
      Ascendis Pharma Q3 2026 Earnings Call Transcript
      Nov 12BenzingaASND
      Ascendis Pharma AS ADR earnings beat by €0.28, revenue topped estimates
      Nov 12Investing.comASND
      Ascendis Pharma stock rises 2% on beating estimates as product sales surge 89%
      Nov 12Investing.comASND
      Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
      Nov 10Yahoo FinanceASNDJEF
      Ascendis Pharma’s TransCon CNP maintains orphan drug status in EU
      Nov 6Investing.comASND
      Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
      Nov 5Yahoo FinanceASND
      S&P 500 Futures Decline in Premarket Trading; Ascendis Pharma, Madrigal Pharmaceuticals Lead
      Nov 3Barron'sASND
      Ascendis Pharma Says Trial Results Show 'Meaningful Improvements' in Kidney Function in Adults with Hypoparathyroidism
      Oct 26Yahoo FinanceASND
      EMA panel backs Ascendis’ achondroplasia drug TransCon CNP
      Oct 16Investing.comASND
      Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia
      Oct 16Yahoo FinanceASND
      UBS Adjusts Ascendis Pharma A/S Price Target to $269 From $307, Maintains Buy Rating
      Oct 15Yahoo FinanceASND
      Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Ascendis Pharma (

      Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 13.7% on an annualized basis producing an average annual return of 27.5%. Currently, Ascendis Pharma has a market capitalization of

      Oct 12BenzingaASND
      Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

      COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of

      Oct 6Yahoo FinanceASND
      This Biotech’s Proprietary Platform Could Unlock Its Next Growth Phase
      Oct 5Yahoo FinanceASND
      Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cytokinetics (CYTK)

      Detailed price information for Cytokinetics (CYTK-Q) from The Globe and Mail including charting and trades.

      Oct 4The Globe and MailASND
      Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

      Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailASND
      BioMarin Grants Ascendis Global License, Secures Royalty Revenues

      Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailASND
      Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Ascendis Pharma (NA

      Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market capitalization of

      Sep 30BenzingaASND
      Ascendis Pharma (ASND) Authorizes $400M Share Buyback

      On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does […]

      Sep 21Yahoo FinanceASND
      Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs
      Sep 19Yahoo FinanceASND
      Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?

      Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

      Sep 17Yahoo FinanceASND
      Ascendis Pharma: Back To Full Independence (NASDAQ:ASND)

      Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and disappointments. Read more on ASND stock here.

      Sep 16Seeking AlphaASND
      Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says

      Ascendis Pharma (ASND) share selloff on Tuesday after the termination of its collaboration agreement

      Sep 16Yahoo FinanceASND
      H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end
      Sep 16Investing.comASND
      Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
      Sep 15BenzingaFDGASNDMEDIMSSM
      Ascendis Pharma at Morgan Stanley conference: cash flow, growth and rights
      Sep 15Investing.comASNDMS
      Raymond James downgrades Ascendis Pharma stock rating on partnership shift
      Sep 15Investing.comASND
      Raymond James Downgrades Ascendis Pharma to Outperform From Strong Buy
      Sep 15Yahoo FinanceASND
      Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback
      Sep 15Yahoo FinanceASND
      Ascendis Pharma authorizes $400 million share buyback program
      Sep 14Investing.comASND
      Ascendis Announces Planned $400 Million Share Repurchase Program

      COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program). Purchases under the planned Share Repurchase Program may be made from time to time, in such amounts as management deems appropriate, through a variety of methods, which may include open market purchases, privately negotiated transactions, b

      Sep 14Yahoo FinanceASND
      $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
      Sep 14BenzingaASND
      BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
      Sep 12Yahoo FinanceASNDBMRN
      Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock
      Sep 10BenzingaASND
      Ascendis Pharma Says Growth Drug Shows Benefits in Infants

      Ascendis Pharma A/S (NASDAQ:ASND) on Wednesday announced Week 52 data from the open-label sentinel cohort of its reACHin trial. The data showed that once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants with achondroplasia aged 0 to under 2 years. Read Also: Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes Growth And Cranio-Cervical Health Treatment with TransCon CN

      Sep 10Yahoo FinanceASND
      H.C. Wainwright reiterates Ascendis Pharma stock rating at buy
      Sep 10Investing.comASND
      TD Cowen reiterates Buy on Ascendis Pharma stock on infant data
      Sep 10Investing.comASND
      BMO reiterates Ascendis Pharma stock rating on infant trial data
      Sep 10Investing.comASND

      This is the newest page. Registered accounts read further back.